← Back to patent-cliff list
Lepetegravir/lenacapavir pacfosaci
Tier C — Watch / tradeLepetegravir/lenacapavir pacfosaci
Gilead Sciences Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：HIV integrase, Capsid
Indications (approved)：HIV infection
Regional status
US
Phase III
2024-08-20
EU
Discontinued
2024-10-21
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Lepetegravir/lenacapavir pacfosaci?
Approved indications include: HIV infection.
When does the Lepetegravir/lenacapavir pacfosaci patent expire?
No public expiry year is available for Lepetegravir/lenacapavir pacfosaci yet; this page updates once verified.
How do I get a quote for Lepetegravir/lenacapavir pacfosaci intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01